2 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Livedoid Vasculopathy: new trials by email Literature Review of Livedoid Vasculopathy trials Research Report on Livedoid Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CSL Behring Sclero XIII Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride - Systemic Sclerosis | Phase 2 | Unknown | University College, London | 26 | 2015-09-01 | 2016-05-30 |
| Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Neovasculgen - Secondary Raynaud's Phenomenon | Phase 1 / Phase 2 | Unknown | Artgen Biotech | 30 | 2015-03-01 | 2015-02-05 |
Raynaud Disease (2) · Scleroderma, Systemic (2) · digital ulcers (1)
Cardiovascular Diseases (2) · Connective Tissue Diseases (2) · Embolism and Thrombosis (2) · Peripheral Vascular Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Thrombosis (2) · Vascular Diseases (2)
Factor VIII (1) · Factor XIII (1) · Saline Solution (1) · Sodium Chloride (1)
Artgen Biotech (1) · University College, London (1)
Russia (1) · United Kingdom (1)
2014 (1)